BLCO
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Bausch + Lomb Corporation (BLCO) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (F). The rating has held at C for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B- (3.1) | C (2.3) | B+ (3.6) | B (3.4) | F (0.0) | C (2.5) |
| 2026-11-10 | B- (3.1) | C (2.3) | B+ (3.6) | B (3.5) | F (0.0) | C (2.5) |
| 2026-11-03 | B- (3.1) | C (2.3) | B+ (3.6) | B (3.4) | F (0.0) | C (2.5) |
| 2026-10-27 | B- (3.1) | C (2.4) | B+ (3.6) | B- (2.9) | C+ (2.6) | B- (2.9) |
| 2026-10-20 | B- (3.1) | C (2.4) | B+ (3.6) | C+ (2.8) | C+ (2.6) | B- (2.9) |